BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 7011299)

  • 1. Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study.
    Laitinen LA; Tokola O; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1981 Jan; 52(1):6-10. PubMed ID: 7011299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
    Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1981 Jun; 52(6):337-9. PubMed ID: 7259691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of experimental motion sickness by scopolamine absorbed through the skin.
    Graybiel A; Knepton J; Shaw J
    Aviat Space Environ Med; 1976 Oct; 47(10):1096-100. PubMed ID: 791234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the effectiveness of drugs for prevention of motion sickness].
    Galle RR; Gusakova GA; Sabaev VV; Galle NN
    Kosm Biol Aviakosm Med; 1988; 22(4):90-4. PubMed ID: 3066982
    [No Abstract]   [Full Text] [Related]  

  • 6. A comparison of the efficacy of cinnarizine with scopolamine in the treatment of seasickness.
    Pingree BJ; Pethybridge RJ
    Aviat Space Environ Med; 1994 Jul; 65(7):597-605. PubMed ID: 7945125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chlorpheniramine and ephedrine in combination for motion sickness.
    Buckey JC; Alvarenga DL; MacKenzie TA
    J Vestib Res; 2007; 17(5-6):301-11. PubMed ID: 18626140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scopolamine (hyoscine) for preventing and treating motion sickness.
    Spinks A; Wasiak J
    Cochrane Database Syst Rev; 2011 Jun; 2011(6):CD002851. PubMed ID: 21678338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological interventions for motion sickness: cardiovascular effects.
    Sunahara FA; Farewell J; Mintz L; Johnson WH
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A270-6. PubMed ID: 3499896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human assay of antimotion sickness drugs.
    Graybiel A; Wood CD; Knepton J; Hoche JP; Perkins GF
    Aviat Space Environ Med; 1975 Sep; 46(9):1107-18. PubMed ID: 1100039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of motion sickness in parabolic flight with buccal scopolamine.
    Norfleet WT; Degioanni JJ; Calkins DS; Reschke MF; Bungo MW; Kutyna FA; Homick JL
    Aviat Space Environ Med; 1992 Jan; 63(1):46-51. PubMed ID: 1550533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of double-dose transdermal scopolamine.
    Bar R; Gil A; Tal D
    Pharmacotherapy; 2009 Sep; 29(9):1082-8. PubMed ID: 19698013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of antimotion sickness drug side effects on performance.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood MJ; Mims ME
    Aviat Space Environ Med; 1985 Apr; 56(4):310-6. PubMed ID: 3888169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Redetzki HM
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A262-5. PubMed ID: 3675502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study.
    Gil A; Nachum Z; Tal D; Shupak A
    Clin Neuropharmacol; 2012; 35(1):37-9. PubMed ID: 22139622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Double-blind crossover trial of pseudoephedrine and triprolidine, alone and in combination, for the treatment of allergenic rhinitis.
    Empey DW; Bye C; Hodder M; Hughes DT
    Ann Allergy; 1975 Jan; 34(1):41-6. PubMed ID: 1098524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scopolamine (hyoscine) for preventing and treating motion sickness.
    Spinks AB; Wasiak J; Villanueva EV; Bernath V
    Cochrane Database Syst Rev; 2007 Jul; (3):CD002851. PubMed ID: 17636710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
    Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
    Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of antimotion sickness medications on the secondary symptoms of motion sickness.
    Wood CD; Stewart JJ; Wood MJ; Manno JE; Manno BR; Mims ME
    Aviat Space Environ Med; 1990 Feb; 61(2):157-61. PubMed ID: 2178599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME; Royal JW; Shaw JE; Schmitt LG
    Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.